HilleVax, Inc. (NASDAQ:HLVX) Director Aditya Kohli Sells 6,000 Shares of Stock

HilleVax, Inc. (NASDAQ:HLVX) Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $15.45, for a total value of $92,700.00. Following the completion of the transaction, the director now owns 776,878 shares of the company’s stock, valued at approximately $12,002,765.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Aditya Kohli also recently made the following trade(s):

• On Wednesday, May 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.73, for a total value of $88,380.00.
• On Friday, May 3rd, Aditya Kohli sold 723 shares of HilleVax stock. The stock was sold at an average price of $14.15, for a total value of $10,230.45.
• On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The stock was sold at an average price of $14.03, for a total value of $2,455.25.
• On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.44, for a total value of $86,640.00.
• On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.93, for a total value of $89,580.00.
• On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $164,221.00, for a total value of $985,326,000.00.
• On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $17.66, for a total value of $105,960.00.
• On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.66, for a total value of $111,960.00.
• On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.95, for a total value of $113,700.00.
• On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.05, for a total value of $90,300.00.

HilleVax Stock Down 2.7 %

Shares of HilleVax stock opened at $14.14 on Thursday. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.11. The business’s 50 day simple moving average is $14.57 and its two-hundred day simple moving average is $14.96. HilleVax, Inc. has a one year low of $9.94 and a one year high of $20.22.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.02. Analysts anticipate that HilleVax, Inc. will post -3.14 EPS for the current year.

Hedge Funds Weigh In On HilleVax

A number of large investors have recently bought and sold shares of HLVX. Federated Hermes Inc. increased its stake in HilleVax by 80.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares during the period. EntryPoint Capital LLC purchased a new position in shares of HilleVax during the first quarter valued at approximately $80,000. SG Americas Securities LLC purchased a new position in shares of HilleVax during the fourth quarter valued at approximately $139,000. Seven Grand Managers LLC purchased a new position in shares of HilleVax during the third quarter valued at approximately $200,000. Finally, Tidal Investments LLC purchased a new position in shares of HilleVax during the first quarter valued at approximately $207,000. 86.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on HLVX shares. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of HilleVax in a research report on Friday, May 10th. JPMorgan Chase & Co. boosted their target price on HilleVax from $21.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 15th.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.